The Centers for Medicare & Medicaid Services today proposed Medicare cover chimeric antigen receptor T-cell (CAR T) therapies approved by the Food and Drug Administration when they are prescribed by the treating oncologist and performed in a hospital meeting certain criteria. The proposed “coverage with evidence development” decision would require eligible patients receiving CAR T to be enrolled in a national registry or CMS-approved clinical study, and followed for at least two years to examine patient outcomes, clinical characteristics and health-related quality of life. The FDA in 2017 approved two CAR T-cell therapies for treating certain leukemias and lymphomas, which require safety monitoring through an FDA risk evaluation and mitigation strategy. The treatments are individually made by modifying the patient’s own T-cells, a type of white blood cell. CMS will accept comments on the proposed coverage decision through March 17. 

Related News Articles

Headline
The Medicare Payment Advisory Commission Friday released its March report to Congress.
Perspective
As our country works to expand health coverage and improve access to care, “Medicare for All” is getting a lot of attention. There are many different flavors…
Headline
Legislative proposals for a Medicare public option could negatively affect patient access to care and significantly reduce payments to hospitals, AHA Executive…
Headline
Creating a government-run, Medicare-like option on the individual health insurance exchanges could negatively affect patient access to care and reduce hospital…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing on the president’s fiscal year 2020 budget request for the Department of Health and…
Headline
President Trump today submitted to Congress his budget request for fiscal year 2020.